[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,147,130
  • Shares Outstanding, K 153,084
  • Annual Sales, $ 616,290 K
  • Annual Income, $ 447,180 K
  • EBIT $ 150 M
  • EBITDA $ 147 M
  • 60-Month Beta 1.68
  • Price/Sales 12.79
  • Price/Cash Flow 18.38
  • Price/Book 13.52

Options Overview Details

View History
  • Implied Volatility 52.34% (-5.29%)
  • Historical Volatility 45.79%
  • IV Percentile 23%
  • IV Rank 16.47%
  • IV High 111.36% on 07/10/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 28) 6.00 (11.28%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 4,348
  • Volume Avg (30-Day) 3,699
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 76,600
  • Open Int (30-Day) 60,580
  • Expected Range 47.22 to 59.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.42
  • Number of Estimates 5
  • High Estimate $0.59
  • Low Estimate $0.31
  • Prior Year $0.17
  • Growth Rate Est. (year over year) +147.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.47 +45.91%
on 06/02/26
54.07 -1.57%
on 06/18/26
+13.74 (+34.80%)
since 05/18/26
3-Month
29.12 +82.78%
on 03/19/26
54.07 -1.57%
on 06/18/26
+23.18 (+77.16%)
since 03/18/26
52-Week
25.28 +110.52%
on 08/11/25
54.07 -1.57%
on 06/18/26
+18.06 (+51.34%)
since 06/18/25

Most Recent Stories

More News
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed...

TGTX : 53.22 (+3.34%)
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or...

TGTX : 53.22 (+3.34%)
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman...

TGTX : 53.22 (+3.34%)
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no...

TGTX : 53.22 (+3.34%)
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies...

TGTX : 53.22 (+3.34%)
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only ...

TGTX : 53.22 (+3.34%)
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with...

TGTX : 53.22 (+3.34%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 53.22 (+3.34%)
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately...

TGTX : 53.22 (+3.34%)
TG Therapeutics Reports Tuesday With Analysts Already Backing Away From Their Own Estimates

Barchart Research What to Expect from TGTX Earnings TGTX Generated May 5, 2026 Current Price $36.10 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Reports Tuesday...

TGTX : 53.22 (+3.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 56.33
2nd Resistance Point 55.20
1st Resistance Point 54.21
Last Price 53.22
1st Support Level 52.09
2nd Support Level 50.96
3rd Support Level 49.97

See More

52-Week High 54.07
Last Price 53.22
Fibonacci 61.8% 43.07
Fibonacci 50% 39.67
Fibonacci 38.2% 36.28
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.